Cytek Biosciences Inc (NAS:CTKB)

$ 5.6 0.03 (0.54%) Market Cap: 735.13 Mil Enterprise Value: 479.43 Mil PE Ratio: 0 PB Ratio: 1.87 GF Score: 60/100

Q1 2024 Cytek Biosciences Inc Earnings Call Transcript
May 08, 2024

$6.27 (-1.72%)

Earnings
Q4 2023 Cytek Biosciences Inc Earnings Call Transcript
Feb 28, 2024

$8.74 (-1.24%)

Earnings
Cytek Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Cytek Biosciences Inc Earnings Call Transcript
Nov 07, 2023

$4.45 (+2.06%)

Earnings
Cytek Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Cytek Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 Cytek Biosciences Inc Earnings Call Transcript
Aug 08, 2023

$8.92 (-2.73%)

Earnings
Cytek Biosciences Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Q1 2023 Cytek Biosciences Inc Earnings Call Transcript
May 09, 2023

$11.67 (+0.60%)

Earnings
Q4 2022 Cytek Biosciences Inc Earnings Call Transcript
Feb 28, 2023

$10.3 (-2.28%)

Earnings
Cytek Biosciences Inc To Acquire Flow Cytometry and Imaging Business From DiaSorin- M&A Call Transcript
Feb 13, 2023
Cytek Biosciences Inc at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Cytek Biosciences Inc at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022
Q3 2022 Cytek Biosciences Inc Earnings Call Transcript
Nov 09, 2022

$13.7 (-5.65%)

Earnings
Cytek Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Q2 2022 Cytek Biosciences Inc Earnings Call Transcript
Aug 10, 2022

$15.45 (+5.17%)

Earnings
Cytek Biosciences Inc Corporate Analyst Meeting Transcript
Jun 22, 2022
Q1 2022 Cytek Biosciences Inc Earnings Call Transcript
May 11, 2022

$7.41 (-7.84%)

Earnings
Q4 2021 Cytek Biosciences Inc Earnings Call Transcript
Feb 23, 2022

$13.12 (-2.53%)

Earnings
Q3 2021 Cytek Biosciences Inc Earnings Call Transcript
Nov 08, 2021

$25.04 (+1.34%)

Earnings
Cytek Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021

Q1 2022 Cytek Biosciences Inc Earnings Call Transcript

May 11, 2022 / 09:00PM GMT

Release Date Price: $7.41 (-7.84%)

Transcript 10-Q8-K

Operator

Thank you for standing by, and welcome to the Cytek Biosciences First Quarter 2022 Earnings Conference Call. (Operator Instructions) As a reminder, today's program may be recorded. And now I'd like to introduce your host for today's program, Paul Goodson, Investor Relations. Please go ahead, sir.

Paul D. Goodson

Cytek Biosciences, Inc. - Head of IR

Thank you, operator. Earlier today, Cytek Biosciences released financial results for the quarter ended March 31, 2022. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to [email protected]. Joining me today from Cytek are Wenbin Jiang, CEO; and Patrik Jeanmonod, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek's business plans, strategies, opportunities and financial projections. These statements involve material risks and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.